Study drug for ER-positive, HER2-negative cancers after treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have advanced or metastatic breast, prostate, or lung cancer that fits this study’s type (for breast: ER-positive and HER2-negative).
- For ER+ HER2- breast cancer: your tumor must be ER-positive (at least 1% positive cells) and HER2-negative (IHC 0/1+ or a negative HER2 gene test).
- Have had enough time since prior treatments (no major surgery, radiation, or anti-cancer therapy within 3 weeks) and side effects must have improved to mild levels.
- Have at least one measurable tumor area that can be measured on scans and has not been previously irradiated.
- Be able to do study activities: ECOG performance status 0 or 1 (you’re fully up and about or limited but still active).
- Meet key safety checks: adequate kidney, liver, and bone marrow function, and an acceptable heart rhythm on ECG. Also must not have pregnancy or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
This study tests a new medicine, PF-08032562, for people with advanced breast or colorectal cancer that has not responded to prior treatments. It aims to see if the drug is safe and can help shrink or slow the cancer.
This trial tests a new pill (M1774) combined with a hormone therapy called fulvestrant for people with advanced hormone-receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The study focuses on people with certain genetic markers in their tumor, hoping the combination will work better than current options.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
This trial tests a new drug (GDC-4198) combined with standard hormone therapies for people with advanced or metastatic breast cancer that is hormone receptor-positive and HER2-negative. It may help by improving the effectiveness of hormone therapy and slowing cancer growth.
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.